Infectious and immunological sequelae of daratumumab in multiple myeloma

Br J Haematol. 2019 Apr;185(1):187-189. doi: 10.1111/bjh.15433. Epub 2018 Jul 5.

Authors

Andrew J Johnsrud¹, Joyce J Johnsrud², Sandra A Susanibar³, Jorge J Kamimoto³, Atul Kothari², Mary Burgess², Frits Van Rhee³, Juan C Rico²

Affiliations

¹ Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
² Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
³ Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

PMID: 29974956
DOI: 10.1111/bjh.15433

No abstract available

Keywords: daratumumab; immunotherapy; multiple myeloma.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Humans
Immunomodulation / drug effects*
Infections / etiology*
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy
Multiple Myeloma / immunology*

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
daratumumab